Quick Order Cart

Cat. No. ARG43776

CBX7 Knockout 769-P Cell Line

  • Product Type:

    In Stock Cell Lines

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Kidney

  • Disease:

    Renal cell carcinoma

The CBX7 Knockout 769-P Cell Line is a CRISPR/Cas9-edited knockout cell line derived from the 769-P renal proximal tubule epithelial cell line. It disrupts the CBX7 gene, which encodes a Polycomb protein that recognizes H3K27me3 and represses transcription via PRC1. The 769-P line originated from a primary clear cell renal cell carcinoma, providing a disease-relevant model for epigenetic studies. CBX7 interacts with PRC1 components RING1B and BMI1, and its loss dysregulates targets like CDKN2A, impacting senescence and proliferation. This cell line is ideal for investigating PRC1 function, chromatin modification, and renal cancer biology using assays such as ChIP-qPCR, senescence staining, and proliferation assays.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    769-P

    Sex of Donor

    Female

    Age

    63 years

    Derived From Site

    In situ; Kidney

    Gene Name

    CBX7

    Gene Identifier

    NCBI Gene ID 23492

    Morphology

    Epithelial-like

    Growth Mode

    Adherent

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Temperature

    37°C

    Atmosphere

    5% COâ‚‚

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. It is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The CBX7 Knockout 769-P Cell Line is a CRISPR/Cas9-edited knockout cell line providing targeted disruption of the CBX7 gene in the 769-P renal cell carcinoma model. This tool enables loss-of-function analysis of the Polycomb group protein CBX7, facilitating investigation of its role in chromatin-mediated gene silencing and tumor biology.

The 769-P cell line originates from a primary clear cell renal cell carcinoma (CCRCC) and exhibits features of renal proximal tubule epithelial cells. It is a widely employed in vitro model for studying CCRCC pathogenesis, including epigenetic alterations and tumor suppressor inactivation, and serves as a relevant system for exploring Polycomb-mediated silencing in kidney cancer.

CBX7 functions as a chromodomain-containing subunit of Polycomb repressive complex 1 (PRC1). It recognizes H3K27me3 marks placed by PRC2 (EZH2) and recruits PRC1 components RING1B, BMI1, and PHC1 to compact chromatin and repress transcription. CBX7 is regulated by AKT phosphorylation, TGF-beta and p53 pathways, and microRNAs including miR-125b, and acts downstream of PRC2. A major target is the CDKN2A locus, where CBX7 silences p16INK4a and p14ARF to inhibit senescence and promote proliferation. In renal cancer, CBX7 may have tumor-suppressive roles, and its loss alters apoptosis and cell cycle programs.

Disruption of CBX7 in the 769-P background allows dissection of its context-dependent functions in renal epithelium. The knockout model helps clarify whether CBX7 acts as an oncogene or tumor suppressor in CCRCC and reveals its impact on global H3K27me3 distribution and PRC1 target gene repression. It also enables studies of compensatory interactions with HDAC1/2 and other chromatin factors.

Researchers can utilize this cell line for chromatin immunoprecipitation (ChIP) assays mapping H3K27me3 and CBX7 occupancy, transcriptomic analysis by RNA-seq, and phenotypic assays for senescence, proliferation, apoptosis, and cell cycle progression using senescence-associated beta-galactosidase staining, MTT, Annexin V, and flow cytometry. It is also suitable for soft agar colony formation and xenograft tumor models to evaluate tumorigenicity. For additional details or collaborative inquiries, please contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)